Tumor-infiltrating lymphocyte quantification stratifies early-stage human papillomavirus oropharynx cancer prognosis

被引:24
作者
Faraji, Farhoud [1 ]
Fung, Nicholas [2 ]
Zaidi, Munfarid [2 ]
Gourin, Christine C. [2 ]
Eisele, David W. [2 ]
Rooper, Lisa M. [3 ]
Fakhry, Carole [2 ,4 ,5 ]
机构
[1] Univ Calif San Diego Hlth, Div Otolaryngol Head & Neck Surg, Dept Surg, San Diego, CA USA
[2] Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA
[3] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD USA
[4] Johns Hopkins, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA
[5] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
关键词
Oropharynx; squamous cell carcinoma; prognosis; human papillomavirus; tumor infiltrating lymphocyte; SQUAMOUS-CELL CARCINOMA; T-CELLS; EXTRACAPSULAR SPREAD; IMMUNE EVASION; HEAD; HPV; SURVIVAL; PREDICT; RISK; RECURRENT;
D O I
10.1002/lary.28044
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives/Hypothesis To evaluate if a simple method for assessing tumor-infiltrating lymphocytes (TIL) in primary tumor specimens improves the prognostic value of the American Joint Committee on Cancer, 8th Edition (AJCC8) cancer staging system in human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV-OPC). Study Design Retrospective study. Methods In this study, TIL density was quantified on hematoxylin and eosin (H&E)-stained specimens from patients presenting to Johns Hopkins Hospital between 2009 and 2017 who underwent primary surgical therapy and had primary tumor specimens available for analysis. The prognostic effect of TIL density was evaluated by Kaplan-Meier method and Cox proportional hazards models considering recurrence-free survival (RFS) as the primary outcome. Results This study included 132 patients. Ninety-five percent were classified by clinical criteria with AJCC8 early-stage disease (stage I: 82%, stage II: 13%). After 84 months of follow-up, 15 recurrences were observed. Among clinically early-stage disease, TILhigh status was associated with improved RFS compared to TILlow (P = .002). Adjusted analysis showed TILhigh status was associated with 79% lower risk of recurrence than TILlow (adjusted hazard ratio [aHR]: 0.210, 95% confidence interval [CI]: 0.061-0.723). In clinical stage I disease, TILhigh status was associated with improved RFS compared to TILlow in both univariate and multivariate analyses (hazard ratio: 0.235, P = .021; aHR: 0.218; 95% CI: 0.058-0.822). TIL density similarly stratified risk in pathologically staged disease. Conclusions In patients with AJCC8 stage I disease, low TIL density was associated with diminished RFS. Our data suggest that assessing TIL density on H&E-stained primary tumor specimens may enhance the prognostic resolution of the AJCC8 staging criteria for HPV-OPC. Level of Evidence 4 Laryngoscope, 130:930-938, 2020
引用
收藏
页码:930 / 938
页数:9
相关论文
共 55 条
  • [1] Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck
    Albers, A
    Abe, K
    Hunt, J
    Wang, J
    Lopez-Albaitero, A
    Schaefer, C
    Gooding, W
    Whiteside, TL
    Ferrone, S
    DeLeo, A
    Ferris, RL
    [J]. CANCER RESEARCH, 2005, 65 (23) : 11146 - 11155
  • [2] An Yi, 2016, Cancers Head Neck, V1, P18, DOI 10.1186/s41199-016-0016-7
  • [3] Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
    Ang, K. Kian
    Harris, Jonathan
    Wheeler, Richard
    Weber, Randal
    Rosenthal, David I.
    Nguyen-Tan, Phuc Felix
    Westra, William H.
    Chung, Christine H.
    Jordan, Richard C.
    Lu, Charles
    Kim, Harold
    Axelrod, Rita
    Silverman, C. Craig
    Redmond, Kevin P.
    Gillison, Maura L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (01) : 24 - 35
  • [4] PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
    Badoual, Cecile
    Hans, Stephane
    Merillon, Nathalie
    Van Ryswick, Cordelia
    Ravel, Patrice
    Benhamouda, Nadine
    Levionnois, Emeline
    Nizard, Mevyn
    Si-Mohamed, Ali
    Besnier, Nicolas
    Gey, Alain
    Rotem-Yehudar, Rinat
    Pere, Helene
    Tran, Thi
    Guerin, Coralie L.
    Chauvat, Anne
    Dransart, Estelle
    Alanio, Cecile
    Albert, Sebastien
    Barry, Beatrix
    Sandoval, Federico
    Quintin-Colonna, Francoise
    Bruneval, Patrick
    Fridman, Wolf H.
    Lemoine, Francois M.
    Oudard, Stephane
    Johannes, Ludger
    Olive, Daniel
    Brasnu, Daniel
    Tartour, Eric
    [J]. CANCER RESEARCH, 2013, 73 (01) : 128 - 138
  • [5] Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials
    Bhatia, Aarti
    Burtness, Barbara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29) : 3243 - +
  • [6] Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx
    Chakravarthy, Ankur
    Henderson, Stephen
    Thirdborough, Stephen M.
    Ottensmeier, Christian H.
    Su, Xiaoping
    Lechner, Matt
    Feber, Andrew
    Thomas, Gareth J.
    Fenton, Tim R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) : 4132 - +
  • [7] Current Status and Future Directions of Treatment Deintensification in Human Papilloma Virus-associated Oropharyngeal Squamous Cell Carcinoma
    Chera, Bhishamjit S.
    Amdur, Robert J.
    [J]. SEMINARS IN RADIATION ONCOLOGY, 2018, 28 (01) : 27 - 34
  • [8] Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
    Cohen, Ezra E. W.
    Soulieres, Denis
    Le Tourneau, Christophe
    Dinis, Jose
    Licitra, Lisa
    Ahn, Myung-Ju
    Soria, Ainara
    Machiels, Jean-Pascal
    Mach, Nicolas
    Mehra, Ranee
    Burtness, Barbara
    Zhang, Pingye
    Cheng, Jonathan
    Swaby, Ramona F.
    Harrington, Kevin J.
    [J]. LANCET, 2019, 393 (10167) : 156 - 167
  • [9] TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?
    De Meulenaere A.
    Vermassen T.
    Aspeslagh S.
    Vandecasteele K.
    Rottey S.
    Ferdinande L.
    [J]. Head and Neck Pathology, 2017, 11 (3) : 354 - 363
  • [10] The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis
    de Ruiter, Emma J.
    Ooft, Marc L.
    Devriese, Lot A.
    Willems, Stefan M.
    [J]. ONCOIMMUNOLOGY, 2017, 6 (11):